References
- Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–1774.
- Banerjee A, Chen S, Fatemifar G, et al. Machine learning for subtype definition and risk prediction in heart failure, acute coronary syndromes and atrial fibrillation: systematic review of validity and clinical utility. BMC Med. 2012;202(19):85.
- Wang W, Kiik M, Peek N, et al. A systematic review of machine learning models for predicting outcomes of stroke with structured data. PLoS ONE. 2020;15(6):e0234722.
- Planell-Morell P, Bajekal M, Denaxas S, et al. Trajectories of disease accumulation using electronic health records. Stud Health Technol Inform. 2020;270:469–473.
- Garibaldi BT, Fiksel J, Muschelli J, et al. Patient trajectories among persons hospitalized for COVID-19: a cohort study. Ann Intern Med. 2021;174(1):33–41. Erratum in: Ann Intern Med. 2021; 174(1):144.
- Jensen AB, Moseley PL, Oprea TI, et al., Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients. Nat Comm. 5(1): 4022. 2014.
- Coravos A, Khozin S, Mandl KD. Developing and adopting safe and effective digital biomarkers to improve patient outcomes. Npj Digit Med. 2019;2(1):14.
- Babrak LM, Menetski J, Rebhan M, et al. Traditional and digital biomarkers: two worlds apart? Digit Biomark. 2019;3(2):92–102.
- Zhang L, Guo H. Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. Adv Biom Sci Technol. 2020;2:1–23.
- Guthrie NL, Carpenter J, Edwards KL, et al. Emergence of digital biomarkers to predict and modify treatment efficacy: machine learning study. BMJ Open. 2019;9(7):1–9.
- Dominietto MD, Capobianco E. Expected impacts of connected multimodal imaging in precision oncology. Front Pharmacol. 2016;7:451.
- Amin S, Bathe OF. Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. BMC Cancer. 2016;16(1):850.
- Mankoff DA, Pryma DA, Clark AS. Molecular imaging biomarkers for oncology clinical trials. J Nucl Med. 2014;55(4):525–528.
- Chennubhotla C, Clarke LP, Fedorov A, et al. An assessment of imaging informatics for precision medicine in cancer. Yearb Med Inform. 2017;26(1):110–119.
- Allen ME, Rus V, Szeto GL. Leveraging heterogeneity in systemic lupus erythematosus for new therapies. Trends Mol Med. 2021;27(2):152–171.
- To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum. 2005;52(12):4003–4010.
- Bossuyt X, De Langhe E, Borghi MO, et al. Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. Nat Rev Rheumatol. 2020;16(12):715–726.
- Nagafuchi Y, Shoda H, Fujio K. Immune profiling and precision medicine in systemic lupus erythematosus. Cells. 2019;8(2):140.
- Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276–289.
- Bartels CM, Rosenthal A, Wang X, et al. Investigating lupus retention in care to inform interventions for disparities reduction: an observational cohort study. Arthritis Res Ther. 2020;22(1):35.
- Barton JL, Trupin L, Schillinger D, et al. Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics. Arthritis Care Res (Hoboken). 2011;63(9):1238–1246.
- Zou Y, Cheung PP, Teoh LK, et al., Sociodemographic factors as determinants of disease, disability and quality of life trajectories in early rheumatoid arthritis: a multi-ethnic inception cohort study. Int J Rheum Dis. 23(1): 55–64. 2020.
- Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. Erratum in: JAMA. 2020;323(20):2098.
- Lowe KE, Zein J, Hatipoglu U, et al. Association of smoking and cumulative pack-year exposure with COVID-19 outcomes in the cleveland clinic COVID-19 registry. JAMA Intern Med. 2021;e208360. DOI:10.1001/jamainternmed.2020.8360.
- Price-Haywood EG, Burton J, Fort D, et al. Hospitalization and mortality among black patients and white patients with Covid-19. N Engl J Med. 2020;382(26):2534–2543.
- Cunningham JW, Vaduganathan M, Claggett BL, et al. Clinical outcomes in young US adults hospitalized with COVID-19. JAMA Intern Med. 2020:e205313. DOI:10.1001/jamainternmed.2020.5313.
- Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F, Bujanda L, et al. Genome-wide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020; 383(16):1522–1534.
- Valenti L, Griffini S, Lamorte G, et al. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. J Autoimmun. 2021;117:102595.
- Alunno A, Najm A, Machado PM, et al. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Ann Rheum Dis. 2021;0:1-9.
- The Lancet editorials. Facing up to long COVID. Lancet. 2020;396(10266):1861.
- Nature editorials. Let patients help define long-lasting COVID symptoms. Nature. 2020;586(7828):170.
- Cortinovis M, Perico N, Remuzzi G. Long-term follow-up of recovered patients with COVID-19. Lancet. 2021;397(10270):173–175.
- Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220–232.